Sara A Abosabie

Ms. Sara A Abosabie

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RSRobin Schmidt
Robin Schmidt
CRChristopher Rueger
Christopher Rueger
HXHan Xu
Han Xu
YHYubei He
Yubei He
EYEmine Yaren Yilmaz
Emine Yaren Yilmaz
LSLynn Jeanette Savic
Lynn Jeanette Savic
Background/Objectives: The aim of this study was to investigate the prognostic value of established response assessment tools for hepatocellular carcinoma (HCC) treated with high-dose-rate interstitial brachytherapy (iBT) alone or with transarterial chemoembolization (cTACE). Methods: (Non-)responders were categorized using size-based RECIST 1.1 and WHO criteria, enhancement-based mRECIST and EASL criteria, and the LI-RADS Treatment Response Algorithm (LR-TRA). The outcomes were the overall survival (OS), progression-free survival (PFS), and time to progression (TTP). The statistics used included Fisher’s exact test, a t-test, the Mann–Whitney-U test, and a Kaplan–Meier analysis. The median OS, PFS, and TTP were higher in patients following iBT (26.3, 9.1, and 13.0 months) than following cTACE/iBT (23.3, 7.6, and 9.2 months). Results: The enhancement-based criteria identified more responders and predicted PFS and TTP better compared to the size-based criteria. At two months, the cTACE/iBT responders showed improved PFS (mRECIST and EASL: 11.3 vs. 2.3 and 11.0 vs. 2.3, p < 0.01) and TTP (mRECIST and EASL: 11.9 vs. 2.4 months, p < 0.01) by the enhancement-based criteria. An EASL assessment at five months predicted improved survival following both cTACE/iBT (PFS: 11.9 vs. 5.1 months, p = 0.03; TTP: 12.4 vs. 5.0, p < 0.01) and iBT (11.1 vs. 5.1 months, p = 0.04; 13.0 vs. 5.3, p < 0.01). The LR-TRA showed OS benefits at five months for cTACE/iBT responders. Size-based criteria were not prognostic. Conclusions: Extending follow-up post-iBT or post-iBT/cTACE may improve responder stratification and prognostication.

5 March 2026 in JHEP Reports
Verified
Journal Article
Open access
SASara A Abosabie
Sara A Abosabie
SASalma A.S. Abosabie
Salma A.S. Abosabie
WDWeicheng Dai
Weicheng Dai
JYJunlin Yang
Junlin Yang
MGMoritz Gross
Moritz Gross
JCJulius Chapiro
Julius Chapiro
There is growing interest in reducing contrast medium use and the lengthy scan duration in liver imaging. This proof of concept study evaluated the feasibility of deep learning-based generation of synthetic 3D liver contrast-enhanced multiphasic magnetic resonance imaging (MRI) exams, which are similar to ground-truth exams in hepatocellular carcinoma and cirrhosis. MRI exams from patients with hepatocellular carcinoma (HCC) or cirrhosis at a single academic center were retrospectively collected. A 3D cycle-consistent generative adversarial network was trained to generate synthetic 3D T1-weighted contrast-enhanced multiphasic liver MRI exams, including arterial, portal venous, delayed, and hepatobiliary phases, using two pre-contrast T1-weighted and T2-weighted input phases. Quantitative performance evaluated similarity, error, and overlap metrics between synthetic and ground-truth exams. For the qualitative multireader study, three blinded radiologists assessed the ground-truth and synthetic MRI exams using a comprehensive questionnaire. Questionnaire tasks 1-5 comprised: visual Turing test (ground-truth vs. synthetic nature), image quality, anatomic accuracy, disease diagnosability, and artifacts. Task 6 comprised Liver Imaging Reporting and Data System features. The study included 3,198 MRI phases from 533 MRI exams from 185 patients with HCC (mean age, 62.1 years ± 9.7 [SD]; 141 men) and 182 patients with cirrhosis (54.4 years ± 10.0; 111 men). Synthetic MRI exams achieved high quantitative and qualitative similarity to ground-truth exams. Quantitative analysis demonstrated high structural similarity index (0.86 ± 0.03), overlap (0.97 ± 0.05), and low symmetric mean absolute percent error (0.63 ± 0.23%). The qualitative multireader study showed no significant difference in tasks 1-5 (p = 0.06-0.50) and high performance metrics in task 6 (accuracy: 0.76-0.86; precision: 0.96-1.00) with moderate to perfect Fleiss's Kappa inter-rater agreement (0.58-1.00, p <0.001). Deep learning enabled the generation of synthetic 3D liver contrast-enhanced multiphasic MRI exams from pre-contrast sequences, achieving high quantitative and qualitative similarity to ground-truth images. This work demonstrates the early feasibility of generating high-quality, 3D contrast-enhanced multiphasic liver MRI exams from pre-contrast sequences, with synthetic exams showing strong agreement with ground-truth across quantitative metrics and key qualitative criteria, including the visual Turing test, image quality, disease diagnosability, anatomic accuracy, artifact severity, and HCC Liver Imaging Reporting and Data System features. Despite the model currently representing a proof of concept based on a moderate single-center dataset, with a need for larger multicenter studies and external validation, the results highlight the potential to transform liver MRI workflows by reducing contrast media costs and potential side effects, significantly shortening acquisition time, especially the prolonged 20-min hepatobiliary phase, and improving accessibility for patients unable to tolerate contrast-enhanced MRI because of renal impairment, contrast agent allergy, or claustrophobia.